Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
November 01 2021 - 4:15PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a conference call and live audio webcast on Monday,
November 8, 2021 at 4:30 p.m. ET to report third quarter 2021
financial results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 1480703. A live webcast of the call can
be accessed under “Events & Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. KORSUVA Injection was approved by the U.S.
Food and Drug Administration (FDA) for the treatment of
moderate-to-severe pruritus associated with chronic kidney disease
(CKD-aP) in adults undergoing hemodialysis on August 23, 2021. Oral
KORSUVA has completed Phase 2 trials for the treatment of pruritus
in patients with CKD and atopic dermatitis and is currently in
Phase 2 trials in primary biliary cholangitis and notalgia
paresthetica patients with moderate-to-severe pruritus.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Janhavi
MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024